DAWN Share Price Performance
US$12.87
3.17 (32.68%)
42.2% undervalued intrinsic discount
US$22.25
Fair Value
Price US$12.87
AnalystConsensusTarget US$22.25
AnalystHighTarget US$30.00
AnalystLowTarget US$17.00
Fair ValueUS$22.25
Share Pricen/a
Day One Biopharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 17 Fair Values set on narratives written by author
DAWN Community Narratives
AN
Fair Value US$22.25 42.2% undervalued intrinsic discount
Expanded Clinical Indications And European Approvals Will Shape Future Oncology
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
Fair Value US$30 57.1% undervalued intrinsic discount
Aging Populations And Regulatory Momentum Will Boost OJEMDA Uptake
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$17 24.3% undervalued intrinsic discount
High Dependency And Losses Will Hamper Growth But Hope Lingers
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Aging Populations And Regulatory Momentum Will Boost OJEMDA Uptake
Key Takeaways Faster-than-expected market penetration and robust global adoption of OJEMDA suggest revenue growth and margin expansion will significantly exceed current forecasts. Strong financial position and innovative commercial strategies position the company for aggressive growth, pipeline investment, and superior long-term earnings leverage.Read more
13
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$30
57.1% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Profit Margin
23.46%
Future PE
35.03x
Price in 2029
US$36.7
High Dependency And Losses Will Hamper Growth But Hope Lingers
Key Takeaways Heavy reliance on a single product and limited portfolio diversify risk, making revenue and growth vulnerable to clinical, regulatory, and market disruptions. Rising regulatory scrutiny and pricing pressures threaten margin expansion, while a lack of international reach further exposes the company to U.S. market shifts.Read more
14
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$17
24.3% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Profit Margin
12.47%
Future PE
52.75x
Price in 2029
US$20.7
Expanded Clinical Indications And European Approvals Will Shape Future Oncology
Key Takeaways OJEMDA's rapid market adoption, expanding clinical use, and broadening regulatory reach position it for durable revenue growth and margin improvement. Strong payer support, disciplined costs, and global demand for precision oncology strengthen revenue stability and reduce future funding dependence.Read more
131
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
US$22.25
42.2% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Profit Margin
16.17%
Future PE
43.72x
Price in 2028
US$27.08
Trending Discussion
Recently Updated Narratives
AN
DAWN: Ojemda Franchise And Mersana Integration Will Recast Future Earnings Power
Fair Value: US$30 57.1% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
DAWN: Future Cash Flows From Mersana Acquisition Will Drive Upside Potential
Fair Value: US$17 24.3% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
DAWN: Mersana Deal Will Diversify ADC Platform And Support Future Upside
Fair Value: US$22.25 42.2% undervalued intrinsic discount
10 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Day One Biopharmaceuticals, Inc. Key Details
About DAWN
- Founded
- 2018
- Employees
- 178
- CEO
- WebsiteView website
Day One Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for childhood and adult diseases with equal intensity in the United States. The company’s lead product candidate is tovorafenib, an oral and brain-penetrant type II rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It is also developing DAY301, a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody conjugated with a topoisomerase I inhibitor via a highly stable and hydrophilic modified valine-alanine (VA) cleavable linker for the treatment of patients with advanced solid tumors; and Emi-Le, an antibody-drug conjugate that targets B7- H4 conjugated to an auristatin anti-tubulin payload as a component of a proprietary linker-payload platform developed by Mersana Therapeutics that is in Phase 1 clinicla trial for the treatment of breast cancer, ovarian cancer, endometrial cancer, and adenoid cystic carcinoma (ACC). Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
